284 related articles for article (PubMed ID: 26033502)
1. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
[TBL] [Abstract][Full Text] [Related]
2. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
3. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
4. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of cancer of unknown primary, today and future].
Shibata H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):918-22. PubMed ID: 19542712
[TBL] [Abstract][Full Text] [Related]
6. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
7. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
8. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
Varadhachary G
Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
[TBL] [Abstract][Full Text] [Related]
9. [Cancer of unknown primary site origin--advances in diagnosis and therapy].
Plot L; Dovrish Z; Hadari R; Weisenberg N; Zehavi T; Nisenbaum B; Amital H
Harefuah; 2008 Apr; 147(4):294-8, 376, 375. PubMed ID: 18686808
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic challenges of patients with carcinoma of unknown primary.
Rassy E; Pavlidis N
Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
[TBL] [Abstract][Full Text] [Related]
11. [CUP syndrome: are there advances?].
Moll R
Verh Dtsch Ges Pathol; 2005; 89():125-36. PubMed ID: 18035682
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma of unknown primary (CUP); some considerations about pathogenesis and diagnostic strategy, particularly focusing on CUPS pertaining to the Urology.
Alberti C
G Chir; 2012; 33(1-2):41-6. PubMed ID: 22357439
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary.
El Rassy E; Khaled H; Pavlidis N
Eur J Cancer; 2018 Dec; 105():28-32. PubMed ID: 30388661
[TBL] [Abstract][Full Text] [Related]
14. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.
Kamposioras K; Pentheroudakis G; Pavlidis N
Eur J Clin Invest; 2013 May; 43(5):491-500. PubMed ID: 23480555
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
van Laar RK; Ma XJ; de Jong D; Wehkamp D; Floore AN; Warmoes MO; Simon I; Wang W; Erlander M; van't Veer LJ; Glas AM
Int J Cancer; 2009 Sep; 125(6):1390-7. PubMed ID: 19536816
[TBL] [Abstract][Full Text] [Related]
16. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
[TBL] [Abstract][Full Text] [Related]
18. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.
Binder C; Matthes KL; Korol D; Rohrmann S; Moch H
Cancer Med; 2018 Sep; 7(9):4814-4824. PubMed ID: 30019510
[TBL] [Abstract][Full Text] [Related]
19. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
20. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]